Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066613 | 1.00 | GPR84 (0.56) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL759431 | 0.89 | GPR84 (0.70) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL425589 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17646227 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1237975 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL584656 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL167865 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL167222 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL165537 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL168064 | 0.82 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | claimed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | claimed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | claimed |
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | disclosed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | DNPEP, LNPEP, RNPEP | GPR84 945/4885FFAR1 1146/4885MAPT 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.